Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma

NCT01377025 is registered in ClinicalTrials.gov with Prof. Dr. med. Max. E. Scheulen as lead sponsor.

NCT NCT01377025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01377025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Lead sponsor
Prof. Dr. med. Max. E. Scheulen
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2011
Completion date
June 30, 2017
Enrollment
200 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma